leadf
logo-loader
viewParadigm Biopharmaceuticals Ltd

Paradigm's drug developments sees growing market opportunities

Paul Rennie, chief executive for Paradigm Biopharmaceuticals, speaks with Proactive Investors.

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: 2.48 AUD

ASX:PAR
Market: ASX
Market Cap: $560.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Paradigm Biopharma CEO 'buoyed, enthusiastic and proud' as it begins dosing...

Paradigm Biopharmaceuticals Ltd's (ASX:PAR) CEO Paul Rennie speaks to Proactive's Andrew Scott after announcing they've initiated a Phase II clinical trial of subcutaneous injectable Pentosan Polysulphate Sodium (iPPS), in patients with the ultra-rare orphan disease Mucopolysaccharidosis Type 1...

on 18/11/20

2 min read